Open company graph database — free web & API
Login

Shionogi Inc.

Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
4,959
Related companies
0
§01

Basic information

BASIC
Head office
5-54 Oosakami, Kita-ku, Osaka City, Grangreen Osaka South Building Park Tower
Chief executive
Isao Teshiyagi
Capital
21,279,742,717 JPY (212 100 millionJPY)
Employees (non-consolidated)
Employees (consolidated)
4,959 people
Start date
1919-06-05
End date
§02

Websites

1 DOMAINS
§03

Business

2
Research, development, manufacturing, and sales of pharmaceuticals.Research, development, manufacturing, and sales of clinical diagnostic reagents and equipment.
§04

Related companies

0 COMPANIES

—

§05

Network

NETWORK
Drag to move · click to open
§06

History

72 EVENTS

Founder Shionogi Saburo established Shionogi Saburo Trading Company in Osaka Midoshi-cho, selling traditional Japanese and Western medicines.Sources

Shionogi Saburo founded the pharmaceutical wholesaler Shionogi Saburo Store on March 17, 1878, at 3-12 Doushou-cho, Osaka.Sources

Transitioned product line to Western medicines.Sources

In 1886, with the spread of Western medicine, began importing and selling Western drugs.Sources

Started direct transactions with Western European and American trading companies.Sources

Produced and sold the first in-house new drug, antacid 'Antacidjin', and registered the 'Bun-Do' mark as a trademark.Sources

In 1909, Choujiro began trial production of an antacid and commercialized the stomach acid neutralizer Antachijin.Sources

In 1909, registered the Bun-dou Mark as a trademark symbolizing trust and reliability.Sources

Constructed the Shionogi Pharmaceutical Factory in Fukushima-ku, Osaka City.Sources

In 1910, built the Shionogi Pharmaceutical Factory and intensified new drug development and manufacturing.Sources

In 1912, launched the heart drug Digitammin, a productized Digitaris preparation introduced by Kondo Heisaburo.Sources

Merged Shionogi Saburo Trading Company and Shionogi Pharmaceutical Factory, reorganized as Shionogi Shoten Co., Ltd.Sources

In 1919, Shionogi Saburo Store and Shionogi Pharmaceutical Factory merged to establish Shionogi Co., Ltd.Sources

Established Kuse Factory in Amagasaki, Hyogo Prefecture (now Kuse Business Office), and set up a laboratory within the factory.Sources

Built a new headquarters building in Osaka Midoshi-cho.Sources

Changed company name to Shionogi Pharmaceutical Co., Ltd.Sources

In 1943, changed the company name to Shionogi Pharmaceutical Co., Ltd.Sources

In 1945, post-war inflation and economic turmoil worsened management; Gisaburo promoted technology improvement and cost reduction to improve management.Sources

Established Yudin Farm in Shiga Prefecture (now Yudin Business Office).Sources

Listed on the Tokyo and Osaka Stock Exchanges.Sources

Released analgesic 'Sedes'.Sources

In 1950, launched the analgesic Sedec.Sources

Released comprehensive vitamin supplement 'Popon S'.Sources

In 1953, worked to strengthen the pharmaceutical business.Sources

Established the basic policy.Sources

In 1957, we inherited a corporate culture that emphasized creating better products, selling them accurately, and focusing on technological development.Sources

Discovered shinomine and established the Detailman system.Sources

In 1958, we transferred plant medicines, animal medicines, and pharmaceutical wholesale to other companies, consolidating our pharmaceutical business.Sources

Released sulfa drug 'Shinomine'.Sources

Constructed Central Research Institute in Fukushima-ku, Osaka City (now consolidated into the Pharmaceutical Research Center).Sources

Established Animal Pharmaceutical Department and Plant Pharmaceutical Department (transferred), started clinical laboratory (transferred), and established Shionogi Pharmaceutical Taiwan (stock).Sources

Broadcast of the company-provided program 'Shionogi Music Fair' startedSources

Construction of Settsu plant (Settsu City, Osaka Prefecture)Sources

Establishment of NIA Pharmaceutical Industry Co., Ltd. (now Shionogi Pharma Co., Ltd.)Sources

Construction of Shionogi Shibuya Building and new drug research institute (Toyonaka City)Sources

Launch of oxacylcephene antibiotic 'Shiomarin'Sources

In 1982, we established a development subsidiary in the United States.Sources

Construction of Kanegasaki factory (Iwate Prefecture)Sources

In 1983, we began joint drug development with GlaxoSmithKline in the United Kingdom.Sources

Construction of Medical Science Research Institute (within Settsu plant site); launch of 'Fullmarin'Sources

Establishment of Shionogi Comprehensive Services Co., Ltd.; acquisition of capsule business from Eli Lilly (later sold)Sources

Construction of new headquarters building in Midosuji, Osaka CitySources

Launch of cephalosporin antibiotic 'Fromax'Sources

Establishment of Shionogi Code of Conduct; establishment of Oomori Pharmaceutical Co., Ltd. (later sold); establishment of Musho Pharmaceutical Co., Ltd. (later sold)Sources

In 1998, we acquired the Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited.Sources

First medium-term management plan startedSources

In April 2000, we established the development subsidiary Shionogi Limited in the United Kingdom.Sources

Establishment of Shionogi USA, Inc.; establishment of Shionogi-GlaxoSmithKline Pharmaceuticals LLC (later Shionogi-ViiV Healthcare LLC); start of joint research on HIV treatment drugsSources

Launch of cancer pain medication 'Oxycontin'Sources

Second medium-term management plan started; launch of 'Crestol' and 'Finibax'Sources

In 2005, we began efforts toward a global basic policy.Sources

Establishment of Shionogi Analytical Center Ltd.; launch of 'Okinome'Sources

Acquisition of US-based Sciele Pharma; launch of 'Irbetan', 'Defirin', 'Pirespa'; opening of joint research facility with Hokkaido UniversitySources

Third medium-term management plan started; launch of 'Rapialact' and 'Sainbarta'; establishment of research instituteSources

In 2010, we formulated a new mid-term management plan and aimed for growth as a drug discovery pharmaceutical company.Sources

Acquisition of Chinese companies, construction of new research institute buildingSources

In 2011, we acquired the Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited.Sources

Establishment of European subsidiary; launch of 'OkiFast' and 'Aimix'Sources

In 2012, we established the development subsidiary Shionogi Limited in the United Kingdom.Sources

Establishment in China and Singapore; royalty contract change; launch of 'Osphena' and 'Ilutra'Sources

SGS2020 Start, launch of TebikeiSources

In 2014, we started a new mid-term management plan aimed at growth as a drug discovery pharmaceutical company.Sources

Launch of Triemek, Asitea, MulpletaSources

SGS2020 Update, establishment of Shionogi Healthcare, launch of Crestor OD tabletsSources

Since May 2016, we have begun promoting flexible business to respond to environmental changes.Sources

Establishment of multiple subsidiaries, launch of Mesapain, Inchunib, Symproic, Suinproik, Oxycodone TR tabletsSources

Establishment of Shionogi Pharma, European subsidiary Shionogi B.V., launch of Zoflura, Mulpleta, JarukaSources

Establishment of M3 joint venture, UMN Pharma subsidiary, opening of training center, launch of Rizmoic, Shufukou, BivanceSources

STS2030 Start, establishment of Heian Shionogi, launch of Fetroja, FetcrojaSources

Since June 2020, we are focusing on drug discovery and advancing initiatives to achieve further growth.Sources

Launch of wastewater epidemiology survey service, Suinproik release in TaiwanSources

Establishment of joint venture AdvanSentinel, Infection Research Promotion Foundation, building group brand and mark, launch of ZocovaSources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑